Short answer
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on April 22, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Filing contains only signature and cover-page references.
SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Filing contains only signature and cover-page references
- No earnings figures or operating results provided in the submitted Item 2.02 text
- Signed April 22, 2026, by CFO Timothy C. Dec
Item EX-99.1 · Exhibit EX-99.1
- First-quarter 2026 results scheduled after market close on May 5, 2026
- Management conference call at 4:30 p.m. ET, providing investors forward guidance and business updates
- Results cover Supernus’s CNS portfolio, including ADHD, Parkinson’s disease, postpartum depression, epilepsy, and migraine treatments
- Investor focus: prescription trends, net revenue, profitability, capital needs, and product-development progress
- Forward-looking risks include regulatory approvals, intellectual-property protection, commercialization, manufacturing capacity, and macroeconomic uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings
Get the next SUPN 8-K as it lands
Follow SUPN for push alerts, or ask the research agent what this filing means.